GSK's oral anemia drug Jesduvroq scores partial FDA nod after 2 rivals suffered rejections

Turns out, the third time is the charm.

After two prior FDA rejections for oral anemia drugs in the hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) drug class, GSK’s daprodustat, branded as Jesduvroq, has won a class-first approval. Specifically, the drug is approved to treat patients with anemia caused by chronic kidney disease who have been on dialysis for at least four months.